The shareholders of Median Technologies (ALMDT: PA) are invited to participate at the Shareholders’ Extraordinary General Meeting which will be held on Friday December 9, 2022, at 4:00 PM at PDGB, 174 avenue Victor Hugo – 75116 Paris.
Read moreMedian Technologies (ALMDT) announced today that the Company will be speaking and presenting at the world’s largest medical imaging conference, the 2022 Radiological Society of North America (RSNA) Annual Meeting and Scientific Assembly, being held in Chicago, IL, USA, Nov. 27 – Dec. 1. The Company will give an industry presentation and two scientific presentations.
Read moreAs of Sep. 30, 2022: Total revenues of €18.7 million, Order backlog of €62.5 million, Cash of €25.9 million. Very strong traction with the launch of Median’s Imaging Lab for the iCRO activity and advanced interactions with the FDA for the iBiopsy® LCS CADe/CADx SaMD clinical pivotal study.
Read moreThe Clinical Advisory Board includes world class physicians and academic leaders in the space of lung cancer and will bring comprehensive expertise on Lung Cancer Screening to guide Median in the development of iBiopsy® LCS AI/ML tech-based CADe/CADx Software as Medical device.
Read moreTo download this content please complete the form below
[contact-form-7 id="5108" title="Download file form"]